A revolutionary gene therapy treatment for heart failure is about to undergo its first international trial at a Scottish hospital.
The first of 200 patients from around the world will be treated at the Golden Jubilee National Hospital, Clydebank, and the Royal Brompton Hospital, London, in the next three to six weeks.
All suffer from severe chronic heart failure, due to the after-effects of heart attacks and inherited conditions.
Doctors will randomly treat half the patients with a harmless virus carrying a corrective gene. The rest will receive an inactive placebo treatment.
Previous research suggests that a protein produced by the gene can restore function to failing hearts, and reduce the risk of death and heart transplants.
Heart failure occurs when the heart is too weak to pump blood efficiently around the body, leading to breathlessness and exhaustion. In severe cases even minor levels of physical activity such as a short walk to the shops prove too much for patients.
Lead investigator Dr Alexander Lyon, consultant cardiologist at the Royal Brompton Hospital, said: "Heart failure affects more than three-quarters of a million people across the UK. Once heart failure starts, it progresses into a vicious cycle where the pumping becomes weaker and weaker, as each heart cell simply cannot respond to the increased demand.
"Our goal is to fight back against heart failure by targeting and reversing some of the critical molecular changes arising in the heart when it fails."
The Cupid 2 trial is taking place in conjunction with US biotech company Celladon, which has patented the treatment.
The therapy involves injecting the virus directly into the heart via a catheter. As the virus infects the heart cells, it implants the corrective gene.
This has the effect of increasing levels of a protein called SERCA2a, which plays a key role in a vital signalling mechanism involving calcium.
"When the heart muscle is injured it activates a series of compensatory changes, but over time fatigue sets in which results in the natural version of this gene switching off," said Dr Lyon. "When the gene is repaired it produces more of the functional protein and the problem is reversed."
Laboratory studies indicate that once the defect is repaired, the gene continues to function, at least over a lengthy period of time.
Some patients from Cupid 1, an earlier pilot trial in the US involving just 39 patients, are still in a stable condition after three years.
Cupid 1 also showed that the gene therapy halved the risk of death, having to undergo a heart transplant, and other serious cardiac events.
The new study will assess whether the treatment is safe, reduces emergency hospital admissions, and improves quality and length of life.
Patients will have their condition monitored for at least 12 months, and the first results should be released in two to three years.
Depending on the outcome, researchers will then move to a larger Phase III trial that could lead to the therapy becoming licensed and generally available after another four or five years.
Professor Sian Harding, head of the British Heart Foundation Centre for Regenerative Medicine at Imperial College London, whose team developed the therapy, said: "It's been a painstaking, 20-year process to find the right gene and make a treatment that works, but we're thrilled to be working with cardiologists to set up human trials that could help people living with heart failure."
Researchers are now going through the process of screening patients for Cupid 2.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article